Serum basic fibroblast growth factor in men with and without prostate carcinoma
β Scribed by Grant E. Meyer; Enyou Yu; Justin A. Siegal; Jason C. Petteway; Brent A. Blumenstein; Michael K. Brawer
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 643 KB
- Volume
- 76
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Carcinomaβassociated fibroblasts (CAF) promote tumor progression of preβneoplastic epithelial cells. To investigate the basis of this phenomenon, we compared the properties of fibroblasts cultured from normal human prostate (NHPF) to prostate CAF. NHPF and CAF were assayed for growth po
Basic fibroblast growth factor (bFGF) and transforming growth factor beta 1 (TGFP1) are potential autocrine growth regulators of the prostatic stroma, and therefore may play a role in the development of benign prostatic hyperplasia (BPH). We reported [Story et al.: Prostate 22:183-197, 19931 that TG
## BACKGROUND. Although growth factors such as epidermal growth factor (EGF), transforming growth factor (TGF)-β£, and TGF-β€ are important regulators of prostate cell growth in vitro and in animal models, evidence to support their role in human prostate cancer development remains sparse. We previous
## BACKGROUND. Basic fibroblast growth factor receptors on DU145 human prostatic carcinoma xenografts serve as targets for the delivery of a growth factor-toxin chimera, basic fibroblast growth factor-saporin (bFGF-SAP), which produces significant antitumor activity in a nude mouse model. However,
Rapid and controlled neoarterial regeneration via perianastomotic as well as transmural tissue ingrowth is critical to patency of implanted small-caliber artificial vascular grafts. Microporous polyurethane (PU) grafts (inner diameter, 1.5 mm; wall thickness, 100 m; length, 20 mm; pore size, 100 m),